Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tAnGo: Gemcitabine in Adjuvant Breast Cancer
NCT00039546Phase 3Unknown
- Sponsor
- CRUK & UCL Cancer Trials Centre
- Start
- Aug 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in breast cancer (2 arms), sponsored by CRUK & UCL Cancer Trials Centre. Primary endpoints: Disease-Free Survival at 10 years and Overall Survival at 10 years. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00039546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039546.